Literature DB >> 21718575

Helicobacter pylori infection.

Grigorios I Leontiadis1, Paul Moayyedi, Alexander Charles Ford.   

Abstract

INTRODUCTION: The principal effect of Helicobacter pylori infection is lifelong chronic gastritis, affecting up to 20% of younger adults but 50% to 80% of adults born in resource-rich countries before 1950. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of H pylori eradication treatment in people with a confirmed duodenal ulcer, a confirmed gastric ulcer, confirmed gastro-oesophageal reflux disease (GORD), confirmed non-ulcer dyspepsia, uninvestigated dyspepsia, localised B cell lymphoma of the stomach, and non-steroidal anti-inflammatory drug (NSAID)-related peptic ulcers? What are the effects of H pylori eradication treatment for preventing NSAID-related peptic ulcers in people with or without previous ulcers or dyspepsia? What are the effects of H pylori eradication treatment on the risk of developing gastric cancer? Do H pylori eradication treatments differ in their effects? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2007 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 58 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: effects of H pylori eradication in different populations; relative effects of triple regimens, quadruple regimens, and sequential regimens.

Entities:  

Mesh:

Year:  2009        PMID: 21718575      PMCID: PMC2907775     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  59 in total

1.  Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.

Authors:  F K Chan; J J Sung; S C Chung; K F To; M Y Yung; V K Leung; Y T Lee; C S Chan; E K Li; J Woo
Journal:  Lancet       Date:  1997-10-04       Impact factor: 79.321

2.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.

Authors:  Jia Qing Huang; Subbaramiah Sridhar; Richard H Hunt
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

3.  Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies.

Authors:  S K Poon; C S Chang; J Su; C H Lai; C C Yang; G H Chen; W C Wang
Journal:  Aliment Pharmacol Ther       Date:  2002-02       Impact factor: 8.171

4.  High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study.

Authors:  Ulrich Peitz; M Sulliga; K Wolle; A Leodolter; U Von Arnim; S Kahl; M Stolte; G Börsch; J Labenz; P Malfertheiner
Journal:  Aliment Pharmacol Ther       Date:  2002-02       Impact factor: 8.171

Review 5.  Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication.

Authors:  M J R Janssen; R J F Laheij; W A de Boer; J B M J Jansen
Journal:  Aliment Pharmacol Ther       Date:  2005-02-15       Impact factor: 8.171

6.  Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial.

Authors:  Naoki Chiba; Sander J O Veldhuyzen Van Zanten; Paul Sinclair; Ralph A Ferguson; Sergio Escobedo; Eileen Grace
Journal:  BMJ       Date:  2002-04-27

7.  Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.

Authors:  J Labenz; A L Blum; W W Bolten; B Dragosics; W Rösch; M Stolte; H R Koelz
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

8.  Relationship between the birth cohort pattern of Helicobacter pylori infection and the epidemiology of duodenal ulcer.

Authors:  R F Harvey; R W Spence; J A Lane; P Nair; L J Murray; I M Harvey; J Donovan
Journal:  QJM       Date:  2002-08

Review 9.  Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis.

Authors:  Javier P Gisbert; Sam Khorrami; Xavier Calvet; José María Pajares
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-01       Impact factor: 2.566

10.  Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project.

Authors:  Richard F Harvey; J Athene Lane; Liam J Murray; Ian M Harvey; Jenny L Donovan; Prakash Nair
Journal:  BMJ       Date:  2004-05-04
View more
  1 in total

1.  ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

Authors:  William D Chey; Grigorios I Leontiadis; Colin W Howden; Steven F Moss
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.